In conclusion, the data presented herein suggest that NEK2 inhibitors may provide a novel approach for increasing the efficacy of FDA-approved CDK4/6 inhibitors in the treatment of aggressive and chromosomally unstable cancers. This evidence concerns the gene CDK4 and cancer.